{
    "summary": "This bill, the 'Innovation in Pediatric Drugs Act of 2025,' primarily aims to amend the Federal Food, Drug, and Cosmetic Act concerning pediatric drug studies. Key provisions include clarifying enforcement related to pediatric study requirements, mandating an FDA report on PREA enforcement (pediatric study requirements), and reforming the application of pediatric research requirements to orphan drugs. It also addresses waiver provisions and requires a GAO study on the impact of these changes.  The bill seeks to improve pediatric drug development by clarifying requirements, providing for transparency, and ensuring due diligence.",
    "tags": [
        "Healthcare",
        "Healthcare access",
        "Consumer protection",
        "Federal agency action",
        "Bipartisanship",
        "Public safety"
    ],
    "category": "Healthcare & Public Health"
}